New trial
Phase I trial of CA-4948 IRAK4/FLT3 inhibitor combined with chemoimmunotherapy in advanced biliary cancer
- Trial ID
- NCT07107750 on ClinicalTrials.gov
- Cancer type
- Biliary Cancer
- Stage of research
- Exploratory
- Location
- Washington University
- Published in
- New in Oncology - Aug 22, 2025
This trial evaluates CA-4948, an IRAK4/FLT3 inhibitor, with gemcitabine (ribonucleotide reductase inhibitor), cisplatin (DNA synthesis inhibitor), and durvalumab (PD-L1 antibody) on a 21-day cycle in treatment-naïve patients with unresectable, advanced biliary adenocarcinoma. Conducted by Washington University School of Medicine, it aims to overcome tumor microenvironment resistance and enhance chemoimmunotherapy efficacy.
More in liver and bile duct cancer
-
New trial · Sep 17, 2026 · NCT07793253
Phase 2 daraxonrasib pan-RAS(ON) tri-complex inhibitor targets KRAS-mutant biliary tract cancer. -
Trial result · Sep 10, 2026 · NCT05301842
STRIDE (durvalumab + tremelimumab) + VEGFR/FGFR TKI lenvatinib + TACE extends PFS in embolisation-eligible HCC -
New trial · Sep 10, 2026 · NCT07780838
Phase 2a pemigatinib FGFR1/2/3 inhibitor alternated with durvalumab PD‑L1 blockade -
New trial · Sep 3, 2026 · NCT07766187
Phase 2 durvalumab PD-L1 inhibitor plus histotripsy non-thermal focused ultrasound ablation in iCCA -
New trial · Aug 27, 2026 · NCT07723534
Phase 2 zolbetuximab CLDN18.2-directed monoclonal antibody + CAPOX/mFOLFOX6 in BTC